Recently, ulotaront, a TAAR1 agonist with 5-HT1A agonist activity, entered Phase 3 clinical trials for the treatment of schizophrenia [19,20], raising the prospect of TAAR1 agonism as a clinical intervention for psychiatric disorders involving hyperdopaminergic signaling. This evidence concerns the gene TAAR1 and schizophrenia.